A small observational study published in JCI Insight (2022) examined individuals with obesity receiving semaglutide who reported reductions in alcohol intake, though the relationship to weight loss requires further investigation in controlled trials
Pharmacy accreditation matters
This product is supplied strictly for laboratory research use only
Secondary Outcomes: Changes from baseline to week 12 in body weight, BMI, fasting blood glucose, fasting insulin (FI), glycated hemoglobin (HbA1c), blood lipids, uric acid, liver function, and testosterone in study participants
Research and Development: The company continues to invest in research to better understand the drugs long-term effects and possibly develop safer alternatives or modifications to existing formulations